标题
Strategies for modern biomarker and drug development in oncology
作者
关键词
Biomarkers, Drug development, Targeted therapies
出版物
Journal of Hematology & Oncology
Volume 7, Issue 1, Pages -
出版商
Springer Nature
发表日期
2014-10-02
DOI
10.1186/s13045-014-0070-8
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Personalized Ovarian Cancer Disease Surveillance and Detection of Candidate Therapeutic Drug Target in Circulating Tumor DNA
- (2015) John A. Martignetti et al. NEOPLASIA
- Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology
- (2014) Edward Rosfjord et al. BIOCHEMICAL PHARMACOLOGY
- Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma
- (2014) Robert J. Motzer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer
- (2014) Mary Jo Fackler et al. CANCER RESEARCH
- A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
- (2014) Jian Zhang et al. Journal of Hematology & Oncology
- Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein
- (2014) Vivek Subbiah et al. Journal of Hematology & Oncology
- Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
- (2014) L Molife et al. Journal of Hematology & Oncology
- A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group
- (2014) Jacqueline Anne Hall et al. LANCET ONCOLOGY
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
- (2014) Aaron M Newman et al. NATURE MEDICINE
- Cancer drivers everywhere?
- (2014) Darren J. Burgess NATURE REVIEWS GENETICS
- The impact of whole-genome sequencing on the reconstruction of human population history
- (2014) Krishna R. Veeramah et al. NATURE REVIEWS GENETICS
- Clinical Benefit Assessment of Vismodegib Therapy in Patients With Advanced Basal Cell Carcinoma
- (2014) B. Dreno et al. ONCOLOGIST
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- Proteomics for discovery of candidate colorectal cancer biomarkers
- (2014) Paula Álvarez-Chaver WORLD JOURNAL OF GASTROENTEROLOGY
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- VEGFA Genomic Amplification Tailors Treatment of HCCs with Sorafenib
- (2014) X. Luo et al. Cancer Discovery
- Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: Current evidence and future perspectives
- (2013) Ana Custodio et al. CANCER TREATMENT REVIEWS
- Detection of Mutant Free Circulating Tumor DNA in the Plasma of Patients with Gastrointestinal Stromal Tumor Harboring Activating Mutations of CKIT or PDGFRA
- (2013) J. Maier et al. CLINICAL CANCER RESEARCH
- Use of Multiple Endpoints and Approval Paths Depicts a Decade of FDA Oncology Drug Approvals
- (2013) M. B. Shea et al. CLINICAL CANCER RESEARCH
- The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma
- (2013) T. K. Choueiri et al. CLINICAL CANCER RESEARCH
- Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
- (2013) G. D. L. Phillips et al. CLINICAL CANCER RESEARCH
- Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non–Small-Cell Lung Cancer
- (2013) Scott A. Laurie et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways
- (2013) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Markers of Response for the Antiangiogenic Agent Bevacizumab
- (2013) Diether Lambrechts et al. JOURNAL OF CLINICAL ONCOLOGY
- ALKin Lung Cancer: Past, Present, and Future
- (2013) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both
- (2013) Nobuyuki Katakami et al. JOURNAL OF CLINICAL ONCOLOGY
- Metabolomic Profiling Identifies Biochemical Pathways Associated with Castration-Resistant Prostate Cancer
- (2013) Akash K. Kaushik et al. JOURNAL OF PROTEOME RESEARCH
- Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
- (2013) Chee Khoon Lee et al. JNCI-Journal of the National Cancer Institute
- Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012
- (2013) Fred R. Hirsch et al. Journal of Thoracic Oncology
- EGFR-directed treatments in SCCHN
- (2013) Everett E Vokes et al. LANCET ONCOLOGY
- Adjuvant bevacizumab: positive data from a negative trial
- (2013) Jose Perez-Garcia et al. LANCET ONCOLOGY
- Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
- (2013) David Cameron et al. LANCET ONCOLOGY
- Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
- (2013) Jan B Vermorken et al. LANCET ONCOLOGY
- Translating metastasis-related biomarkers to the clinic—progress and pitfalls
- (2013) François-Clément Bidard et al. Nature Reviews Clinical Oncology
- Implementing personalized cancer genomics in clinical trials
- (2013) Richard Simon et al. NATURE REVIEWS DRUG DISCOVERY
- Molecular genetic testing and the future of clinical genomics
- (2013) Sara Huston Katsanis et al. NATURE REVIEWS GENETICS
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
- (2013) Sarah-Jane Dawson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody Therapeutics in Cancer
- (2013) M. X. Sliwkowski et al. SCIENCE
- Monitoring the Clinical Outcomes in Advanced Prostate Cancer: What Imaging Modalities and Other Markers Are Reliable?
- (2013) Michael J. Morris et al. SEMINARS IN ONCOLOGY
- Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
- (2013) A. O. Walter et al. Cancer Discovery
- Adjuvant therapy in primary GIST: state-of-the-art
- (2012) P. Reichardt et al. ANNALS OF ONCOLOGY
- Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
- (2012) Dorte L. Nielsen et al. BREAST
- Antibody-Drug Conjugates for the Treatment of Cancer
- (2012) John A. Flygare et al. Chemical Biology & Drug Design
- 18F-FDG-PET/CT Imaging as an Early Survival Predictor in Patients with Primary High-Grade Soft Tissue Sarcomas Undergoing Neoadjuvant Therapy
- (2012) K. Herrmann et al. CLINICAL CANCER RESEARCH
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials
- (2012) C. Giessen et al. CLINICAL CANCER RESEARCH
- Novel Strategies to Test Biological Hypotheses in Early Drug Development for Advanced Prostate Cancer
- (2012) R. Ferraldeschi et al. CLINICAL CHEMISTRY
- Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
- (2012) Joo Ern Ang et al. CURRENT DRUG TARGETS
- Adjuvant Therapy for High-Risk Gastrointestinal Stromal Tumour
- (2012) Heikki Joensuu DRUGS
- 409 Optimizing the Therapeutic Potential of PD-L1 Blockade as a Single Agent and Through Combination Therapy
- (2012) B. Irving et al. EUROPEAN JOURNAL OF CANCER
- Breast cancer biomarkers: proteomic discovery and translation to clinically relevant assays
- (2012) Liping Chung et al. Expert Review of Proteomics
- Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer
- (2012) Andrew J. Weickhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Genomics: Technology, Discovery, and Translation
- (2012) Ben Tran et al. JOURNAL OF CLINICAL ONCOLOGY
- Association ofKRASG13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
- (2012) Sabine Tejpar et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
- (2012) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- (2012) Vincent A Miller et al. LANCET ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Quantitative assessment of dynamic PET imaging data in cancer imaging
- (2012) Mark Muzi et al. MAGNETIC RESONANCE IMAGING
- Promise and pitfalls of quantitative imaging in oncology clinical trials
- (2012) Brenda F. Kurland et al. MAGNETIC RESONANCE IMAGING
- Mass spectrometry-based proteomics: The road to lung cancer biomarker discovery
- (2012) Paola Indovina et al. MASS SPECTROMETRY REVIEWS
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
- (2012) Aleksandar Sekulic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance
- (2012) C. M. Lovly et al. Science Translational Medicine
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)
- (2012) Toni K. Choueiri et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
- (2012) Hubing Shi et al. Nature Communications
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
- (2011) C. Bokemeyer et al. ANNALS OF ONCOLOGY
- Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics
- (2011) Timothy A. Yap et al. Annual Review of Pharmacology and Toxicology
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
- (2011) T. Sasaki et al. CANCER RESEARCH
- Combinatorial Treatments That Overcome PDGFR -Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition
- (2011) H. Shi et al. CANCER RESEARCH
- Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer
- (2011) Matthew G. Krebs et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations
- (2011) Jeeyun Lee et al. JNCI-Journal of the National Cancer Institute
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Deep proteome and transcriptome mapping of a human cancer cell line
- (2011) N. Nagaraj et al. Molecular Systems Biology
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
- (2011) R. Katayama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Diffusion and Diffusion Tensor Imaging in Brain Cancer
- (2011) Elizabeth R. Gerstner et al. SEMINARS IN RADIATION ONCOLOGY
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2010) C. Pena et al. CLINICAL CANCER RESEARCH
- Targeted high throughput sequencing of a cancer-related exome subset by specific sequence capture with a fully automated microarray platform
- (2010) Daniel Summerer et al. GENOMICS
- A window into third-generation sequencing
- (2010) E. E. Schadt et al. HUMAN MOLECULAR GENETICS
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Awakening Immunity
- (2010) H. Schreiber et al. SCIENCE
- Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy
- (2009) Jian-Mei Hou et al. AMERICAN JOURNAL OF PATHOLOGY
- Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
- (2009) E. D. Saad et al. ANNALS OF ONCOLOGY
- Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
- (2009) S. George et al. EUROPEAN JOURNAL OF CANCER
- Targeted comparative genomic hybridization array for the detection of single- and multiexon gene deletions and duplications
- (2009) Marwan K Tayeh et al. GENETICS IN MEDICINE
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
- (2009) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
- (2009) Howard I Scher et al. LANCET ONCOLOGY
- Fundamentals of Quantitative Dynamic Contrast-Enhanced MR Imaging
- (2009) Michael J. Paldino et al. Magnetic Resonance Imaging Clinics of North America
- Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
- (2009) Arun Sreekumar et al. NATURE
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
- (2009) Wenjun Zhou et al. NATURE
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
- (2009) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Basic Principles and Technologies for Deciphering the Genetic Map of Cancer
- (2009) Georgios Voidonikolas et al. WORLD JOURNAL OF SURGERY
- Molecular Pathobiology of Gastrointestinal Stromal Sarcomas
- (2008) Christopher L. Corless et al. Annual Review of Pathology-Mechanisms of Disease
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
- (2008) J. S. de Bono et al. CLINICAL CANCER RESEARCH
- Microarray Technology and Applications in the Arena of Genome-Wide Association
- (2008) S. F. A. Grant et al. CLINICAL CHEMISTRY
- Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
- (2008) Andrew D. Seidman et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
- (2008) Steven J. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
- (2008) Alberto F. Sobrero et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
- (2008) Michael C. Heinrich et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive Disease Small Cell Lung Cancer
- (2008) Ji-Youn Han et al. Journal of Thoracic Oncology
- HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer
- (2008) Soonmyung Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now